Since it is known that Ang-(1–7) levels are raised upon treatment with ACE inhibitors or AT1 receptor blockers and that they contribute to the beneficial effects in preventing diabetes-induced end-organ damage [24, 30], our data further leads us to speculate that Ang-(1–7) effects may be partly mediated via α1-adrenoceptor blockade of ErbB2 transactivation. Here, ERBB2 is linked to diabetes mellitus.